Previous 10 | Next 10 |
Gainers: BELLUS Health (NASDAQ:BLU) +26%, aTyr Pharma (NASDAQ:LIFE) +22%, Jounce Therapeutics (NASDAQ:JNCE) +14%, NanoViricides (NYSE:NNVC) +12%, Matinas BioPharma (NYSE:MTNB) +12%. Losers: Virpax Pharmaceuticals (NASDAQ:VRPX) -37%, RedHill Bi...
The following slide deck was published by Jounce Therapeutics, Inc. in conjunction with this event. For further details see: Jounce Therapeutics (JNCE) Corporate Presentation
Jounce Therapeutics, Inc. (JNCE) Q2 2021 Earnings Conference Call August 05, 2021 08:00 A.M. ET Company Participants Mark Yore - Director of Corporate Development Richard Murray - CEO and President Elizabeth Trehu - CMO Dmitri Wiederschain - Chief Scientific Officer Kim Drapkin - CFO Conferen...
The following slide deck was published by Jounce Therapeutics, Inc. in conjunction with their 2021 Q2 earnings call. For further details see: Jounce Therapeutics, Inc. 2021 Q2 - Results - Earnings Call Presentation
Image source: The Motley Fool. Jounce Therapeutics, inc (NASDAQ: JNCE) Q2 2021 Earnings Call Aug 5, 2021 , 8:00 a.m. ET Operator Continue reading For further details see: Jounce Therapeutics, inc (JNCE) Q2 2021 Earnings Call Transcript
Jounce Therapeutics (NASDAQ:JNCE): Q2 GAAP EPS of -$0.08 beats by $0.28. Revenue of $25.4M beats by $17.24M. As of June 30, 2021, cash, cash equivalents and investments were $246.1 million, compared to $213.2 million as of December 31, 2020. Press Release For further details see: ...
- INNATE monotherapy dose escalation enrollment completed and target dose selected, on track to initiate indication specific expansions in third quarter 2021- - Announced two additional LILRB family targets as potential future development candidates - - Ended the qu...
CAMBRIDGE, Mass., July 29, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that it will report second quarter 2021 financial result...
Jounce is a clinical stage biotech company that is attempting to transform the treatment of cancer by developing novel immunotherapies. The science is promising, but still in its early stages. A license deal with Gilead has provided credibility to Jounce's platform and helped to s...
CAMBRIDGE, Mass., July 07, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that Dmitri Wiederschain, Ph.D., Chief Scientific Office...
News, Short Squeeze, Breakout and More Instantly...
Jounce Therapeutics Inc. Company Name:
JNCE Stock Symbol:
NASDAQ Market:
Jounce Therapeutics Inc. Website:
CAMBRIDGE, Mass., May 03, 2023 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE) (“Jounce” or the “Company”), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that Co...
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION. CAMBRIDGE, Mass., April 03, 2023 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. ("Jounce" or t...
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION. CAMBRIDGE, Mass., March 27, 2023 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE)...